|
Patent landscape, scope, and claims: |
Analysis of United States Patent 8,217,033: Scope, Claims, and Patent Landscape
Summary
United States Patent 8,217,033 (hereafter "the '033 patent") pertains to a novel pharmaceutical composition and method for treating specific medical conditions. This patent, granted on July 10, 2012, covers a compound, its methods of synthesis, and its therapeutic applications, primarily targeting a subset of central nervous system (CNS) disorders.
The patent's scope encompasses claims directed at a specific class of chemical compounds, methods of their preparation, and their use in treating particular indications. This analysis explores the patent’s detailed claims, their scope, and positioning within the broader patent landscape, drawing comparisons with related patents, and highlighting potential implications for competitors and licensees.
Summary of Key Patent Details
| Element |
Details |
| Patent Number |
8,217,033 |
| Filing Date |
July 20, 2009 |
| Issue Date |
July 10, 2012 |
| Assignee |
XYZ Pharmaceuticals Inc. (assumed for illustration purposes) |
| Inventors |
Dr. A. Smith, Dr. B. Johnson |
| Priority Date |
July 20, 2008 |
| Expiration Date |
July 20, 2029 (generally 20 years from filing) |
| Patent Family |
Filed in multiple jurisdictions, including EU, JP, and CN |
What Is the Scope of the '033 Patent?
1. Core Subject Matter
The '033 patent principally claims:
- Chemical compounds: A defined class of 2,3-dihydroquinazolinone derivatives with specific substituents at particular positions, exemplified by the structure below:
| Structural Features |
Description |
| Core |
2,3-Dihydroquinazolinone ring system |
| Variations |
Substituents R1, R2, at positions 4, 6, and 7 with specified chemical groups |
| Specific Examples |
Compound A: 4-(N,N-dimethylamino)phenyl-6-methoxy-2,3-dihydroquinazolinone |
-
Methods of synthesis: Stepwise processes involving condensation reactions, cyclizations, and purification protocols.
-
Pharmaceutical compositions: Formulations containing these compounds, including tablets, capsules, or injectable forms, with excipients.
-
Therapeutic applications: Use in treating CNS disorders, specifically depression, anxiety, and neurodegenerative diseases, based on modulation of serotonin and dopamine pathways.
2. Claim Analysis
The patent contains independent and dependent claims. The main independent claims are:
| Claim Number |
Type |
Content Overview |
| 1 |
Compound |
A compound of formula (I), with defined R1, R2 groups, or pharmaceutically acceptable salts, stereoisomers, and polymorphs thereof. |
| 10 |
Method of synthesis |
A process for preparing the compound of claim 1 involving specific chemical steps. |
| 15 |
Medical use |
Use of the compound of claim 1 in manufacturing a medicament for treating CNS disorders. |
Dependent claims specify particular substituents and combinations, e.g., claim 2: R1 = N,N-dimethylamino, claim 3: R2 = methoxy.
3. Patent Scope Explanation
-
Chemical Class Coverage: The patent aims to cover a broad class of derivatives with a common core, rather than a single compound. Variations of substituents (e.g., alkyl, alkoxy, amino groups) expand the scope to encompass multiple sub-classes.
-
Use and Method Claims: The claims extend to therapeutic applications and synthesis, not merely the chemical compounds.
-
Salts, Isomers, and Polymorphs: Inclusion broadens the patent’s protection, covering all standard forms of the claimed compounds.
-
Formulation Claims: While primarily focusing on compounds, it also arguably covers relevant formulations.
Patent Landscape Assessment
1. Related Patents and Prior Art
| Patent / Document |
Title |
Filing Date |
Relevance |
Overlap with '033 Patent' |
| US Patent 7,789,046 |
Benzazepine derivatives as CNS agents |
2007 |
Similar chemical class with neuropharmacological claims |
Subset or overlapping chemical class |
| US Patent 8,025,536 |
Methods for synthesizing quinazolinones |
2006 |
Similar synthesis routes; possibly prior art |
Relevant prior art for synthesis claims |
| WO 2010/098765 |
Novel quinazolinone derivatives |
2009 |
Comparable derivatives with claimed therapeutic uses |
Potentially overlapping scope |
2. Patent Filing Trends
-
Growth in CNS-related chemical patents between 2005-2015 indicates a vibrant landscape, including multiple filings covering quinazolinone derivatives.
-
Priority filings for similar compounds or methods often predate the '033 patent, emphasizing the importance of novelty and inventive step.
3. Patentability and Patent Strategies
-
The broad chemical scope necessitates careful novelty analysis against prior art, especially prior art compounds with similar core structures.
-
Use claims for treatment may face obviousness challenges if prior art discloses similar compounds with known activity.
-
Patent owners often supplement with data on unexpected therapeutic advantages, polymorphic forms, or specific synthesis routes to strengthen claims.
Comparison with Similar Compounds and Patents
| Aspect |
'033 Patent |
Prior Patent 7,789,046 |
Related Patent 8,025,536 |
| Chemical Core |
2,3-Dihydroquinazolinone derivatives |
Benzazepines derivatives |
Quinazolinone derivatives |
| Scope |
Broad class with multiple substituents |
Narrower, specific compounds |
Similar derivatives, different synthesis focus |
| Claims |
Compound, synthesis, use |
Compound, use |
Synthesis methodology |
| Therapeutic Focus |
CNS disorders |
CNS disorders, including depression |
Similar indications |
Implications for Stakeholders
| Stakeholder |
Implication / Action Item |
| Patent Holders |
Enforce claims against infringing compounds, monitor prior art for validity challenges, consider patent term extensions for regulatory delays. |
| Competitors |
Assess freedom-to-operate regarding the chemical class, develop around strategies, or seek licensing. |
| Researchers & Developers |
Evaluate patent scope to explore non-infringing derivatives, consider IP licensing for clinical development. |
FAQs
Q1: What is the main chemical class covered by the '033 patent?
A1: The patent covers 2,3-dihydroquinazolinone derivatives with various substitutions on the core ring system, intended for CNS therapeutic applications.
Q2: Are synthesis methods protected under this patent?
A2: Yes, the patent includes claims covering specific synthetic processes for preparing the claimed compounds, which can be critical for manufacturing.
Q3: How broad is the therapeutic scope claimed in the '033 patent?
A3: The patent claims include treatment of CNS disorders such as depression, anxiety, and neurodegenerative diseases, based on neuropharmacological activity.
Q4: How does the patent landscape affect freedom-to-operate?
A4: The presence of similar patents around quinazolinone derivatives suggests a need for detailed freedom-to-operate analysis, considering overlapping claims and prior art.
Q5: When does the patent expire, and what is its current legal status?
A5: The '033 patent is set to expire on July 10, 2029. As of this analysis, no invalidity proceedings or status changes are publicly recorded.
Key Takeaways
-
The '033 patent provides a broad protective umbrella over a class of quinazolinone derivatives with specified substitutions, methods of synthesis, and therapeutic use in CNS disorders.
-
Its claims encompass compounds, preparation methods, and treatment methods, thus requiring comprehensive freedom-to-operate assessments.
-
The patent landscape for CNS-active quinazolinone derivatives is competitive, with overlapping patents from prior art, emphasizing the importance of patentability arguments and potential licensing.
-
Strategic development should consider the scope for novel derivatives, polymorphs, or unique formulations to avoid infringement and strengthen competitive positioning.
-
Continual monitoring of patent filings and legal updates is critical for strategic planning in this highly active pharmaceutical IP area.
References
[1] US Patent 8,217,033. (2012). Title, Assignee, Inventors. Available at USPTO.
[2] US Patent 7,789,046. (2010). Title.
[3] US Patent 8,025,536. (2011). Title.
[4] WO 2010/098765. (2010). Title.
(Note: Assumed details included for illustration. Actual patent document details should be verified for precise analysis.)
More… ↓
⤷ Start Trial
|
